The Life Sciences team advised Korro Bio, Inc. $116 million Series B financing.
Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines.
This financing will enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited genetic disorder leading to liver and lung disease, while expanding its pipeline to address prevalent diseases across multiple therapeutic areas.
The Goodwin team was led by Daniel Hughes, and Kingsley Taft.
For more details, read the press release and articles in Endpoints, Fierce Biotech, and Boston Business Journal.
Find out more about Life Sciences and Life Sciences Emerging Companies today.
Find out more about Korro Bio
Korro is an RNA editing company that is focused on the discovery and development of new precision genetic medicines.
Korro’s proprietary and modular platform, OPERATM, uses data-driven design in combination with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This innovative technology combines the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety, in a cost-effective drug product.
As a consequence, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases.